Accurate calculation of prostate-specific antigen doubling time can be crucial for prostate cancer treatment decisions but is ...

Immune therapy has transformed how cancer is treated, but many tumors continue to evade these treatments, thanks to their ...

A systematic review and meta-analysis explored the relationship between androgen deprivation therapy and risk for heart failure in men with prostate cancer who were treated with ADT. A meta-analysis ...

There are currently 82,000 incident cases of RCC annually in the United States (account for 3–5% of cancers), with 15,000 deaths annually in the United States. The overall 5-year mortality risk is ~30 ...

Introduction Cancer and its treatments can lead to a wide range of ... While inclusive eligibility criteria will be applied; this will in turn lead to heterogeneity which facilitates mapping of the ...

Barry Goy, MD, provides insight into the clinical implications of a retrospective analysis examining 15-year outcomes in patients with intermediate-risk prostate cancer.

Among those with intermediate-risk prostate cancer, high PSA levels prior to HIFU led to an increased risk of overall ...

Cancer researcher Karen Sfanos says she is 'terrified' of the impact of cuts to NIH funding that supports vital biomedical ...

Van Andel Institute researchers discovered that cancer risk may be determined before birth due to distinct epigenetic states ...

Data on enfortumab vedotin plus pembrolizumab for advanced bladder cancer, along with updates on antibody-drug conjugates, ...

After an apparent accidental early release, Pfizer has revealed phase 1 data showing its investigational candidate, alongside ...